Published by Josh White on 21st January 2026
(Sharecast News) - Avacta Therapeutics said on Wednesday that it has received clearance from the US Food and Drug Administration for the investigational new drug application for 'FAP-Exatecan', or AVA6103, marking the transition of its second 'preCISION' medicine from preclinical development into human trials.